FOURIER trial
A cardiovascular outcome trial for Evolocumab (a PCSK9 inhibitor) in patients with stable ASCVD, showing a 15% reduction in major adverse cardiovascular events.
Save the 4 videos on FOURIER trial to your own pod.
Sign up free to keep building your knowledge base on FOURIER trial as more episodes are added.
Videos Mentioning FOURIER trial
Cardiovascular disease & why we should change the way we assess risk | The Peter Attia Drive Podcast
Peter Attia MD
A clinical trial for the PCSK9 inhibitor Repatha, which showed a reduction in cardiac revascularization but no change in mortality over a five-year period in heavily statinized patients with very low LDL-C.
#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain
Peter Attia MD
A landmark trial demonstrating that PCSK9 inhibitors (Repatha) significantly reduce cardiovascular events in patients with already low LDL-C on statins, even over a short period.
230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more
Peter Attia MD
A cardiovascular outcome trial for Evolocumab (a PCSK9 inhibitor) in patients with stable ASCVD, showing a 15% reduction in major adverse cardiovascular events.
210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.
Peter Attia MD
A cardiovascular outcomes trial that tested PCSK9 inhibitors in patients already on statins, showing a 15% reduction in relative risk of cardiovascular events over 2.2 years.